Mexico Pushes for US Trade Deal Before Midterms 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
Gold Prices Hold Steady Ahead of Trump-Xi Summit, Middle East Risks 
Europe Jet Fuel Deficit Drives South Korean Imports to Four-Year High 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
Lula Meets Mamdani in New York as Elections Approach 
Zelenskiy Meets CIA Chief John Ratcliffe at Ireland’s Shannon Airport 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
Canada Unveils Bill to Fast-Track Major Resource Projects 
Trump Plans Military Complex Inside Washington Triumphal Arch 
S&P 500 Historically Rallies After Midterm Elections, UBS Says 
ICE Officer Shoots Man in Austin, Sparking Calls for Independent Probe 
UK Home Asking Prices Rise for First Time Since May 
Russian Drone Attacks Kill Four in Kyiv Region, Including Three Children 
U.S. Dollar Hits Eight-Week High After Fed Rate Hike 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Trump Sets High-Stakes UN Meetings With Zelenskiy, Gulf Leaders 
Add as a preferred source on Google
US healthcare stocks have fallen sharply following President-elect Donald Trump's cabinet picks. The nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services has alarmed investors due to his critical stance on vaccines and obesity drugs, sparking fears of significant regulatory shifts.
Trump's Election Spurs Healthcare Stock Decline in US and Europe
Barclays reports that since Donald Trump's election on November 5, healthcare stocks in the US and Europe have fallen due to growing concerns about the possible policy effects of his cabinet nominees, Investing.com shares.
The healthcare industry as a whole has lagged larger indexes; for example, the U.S. healthcare ETF is down nearly 7% from the S&P 500, and healthcare equities in Europe are down roughly 1.5% from the broader European index.
There have been strong protests to Robert F. Kennedy Jr.'s nomination to head HHS, particularly in the pharmaceutical and biotech industries.
Kennedy's Controversial Stance on Vaccines and Obesity Drugs
Possible regulatory roadblocks have been heightened by Kennedy's reputation for vaccination skepticism and criticism of obesity medications.
Concerns have been raised by Kennedy's remarks on the FDA's policy, vaccines, and GLP-1 medications for obesity.
It may be difficult to turn these ideas into practical policy, according to analysts at Barclays.
Medicare only pays for GLP-1 medications, such as Novo Nordisk semaglutide, for obese individuals who meet the SELECT trial's criteria for shown cardiovascular risk. Modifications to the Treat and Reduce Obesity Act (TROA) would be necessary to expand coverage.
Barclays Sees Opportunity Despite Investor Skepticism
The commercial market, not Medicaid or Medicare, is the main driver of growth for anti-obesity pharmaceuticals, according to Barclays.
Regarding vaccination policies, investors are even more skeptical due to Kennedy's anti-vaccine stance.
As a result of Kennedy's nomination, Novo Nordisk and Sanofi stocks have been "unduly punished," according to Barclays. Barclays sees the selloff as an overreaction and has maintained "overweight" ratings for both firms.
While healthcare is still facing some short-term problems, Barclays does point out that certain subsectors might eventually profit from more defined rules.
Broader Cabinet Picks Add to Market Uncertainty
Even more so than with Kennedy's nomination, investors are worried about regulatory uncertainty due to Trump's wider cabinet nominations, such as Vivek Ramaswamy to the Department of Government Efficiency.
